Ranolazine in patients with coronary artery disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 13, 2007, Pages 2149-2157

  Scirica, Benjamin M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic angina; Ischemia; Pharmacotherapy; Ranolazine

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DIGOXIN; DILTIAZEM; DOFETILIDE; FASUDIL; IVABRADINE; KETOCONAZOLE; MACROLIDE; NICORANDIL; NIFEDIPINE; NITRATE; PLACEBO; PROTEINASE INHIBITOR; RANOLAZINE; SIMVASTATIN; SODIUM; SOTALOL; TRIMETAZIDINE; VERAPAMIL; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CALCIUM CELL LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONARY ARTERY DISEASE; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EXERCISE TOLERANCE; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART RATE; HUMAN; HYPOTENSION; LONG TERM CARE; MONOTHERAPY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; QT PROLONGATION; RECURRENCE RISK; RISK REDUCTION; SODIUM CELL LEVEL; SODIUM CURRENT; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; SYNCOPE; UNITED STATES; WEAKNESS; CORONARY ARTERY ATHEROSCLEROSIS; MORTALITY; PATHOPHYSIOLOGY; REVIEW;

ACETANILIDES; ANGINA PECTORIS; CORONARY ARTERIOSCLEROSIS; HUMANS; PIPERAZINES;

EID: 34548621588     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.13.2149     Document Type: Article

References (25)

1. THOM T, HAASE N, ROSAMOND W et al.: Heart disease and stroke statistics-2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation (2006) 113(6):E85-E151.
2. MUKHERJEE D, BHATT DL, ROE MT, PATEL V, ELLIS SG: Direct myocardial revascularization and angiogenesis - how many patients might be eligible? Am. J. Cardiol. (1999) 84(5):598-600.
3. CAMICI PG, CREA F: Coronary microvascular dysfunction. N. Engl. J. Med. (2007) 356(8):830-840.
4. REIS SE, HOLUBKOV R, CONRAD SMITH AJ et al.: Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am. Heart J. (2001) 141(5):735-741.
5. ABRAMS J: Clinical practice. Chronic stable angina. N. Engl. J. Med. (2005) 352(24):2524-2533.
6. ABRAMS J, THADANI U: Therapy of stable angina pectoris: the uncomplicated patient. Circulation (2005) 112(15):E255-259.
7. HEIDENREICH PA, MCDONALD KM, HASTIE T et al.: Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA (1999) 281(20):1927-1936.
8. BORER JS, FOX K, JAILLON P, LEREBOURS G: Anti-anginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation (2003) 107(6):817-823.
9. IONA STUDY GROUP: Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet (2002) 359(9314):1269-1275.
10. VICARI RM, CHAITMAN B, KEEFE D et al.: Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, Phase II trial. J. Am. Coll. Cardiol. (2005) 46(10):1803-1811.
11. MANCHANDA SC, KRISHNASWAMI S: Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart (1997) 78(4):353-357.
12. MARZILLI M, KLEIN WW: Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron. Artery Dis. (2003) 14(2): 171-179.
13. MACINNES A, FAIRMAN DA, BINDING P et al.: The anti-anginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. (2003) 93(3):E26-E32.
14. WANG P, FRASER H, LLOYD SG et al.: A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J. Pharmacol. Exp. Ther. (2007) 321(1):213-220.
15. BELARDINELLI L, SHRYOCK JC, FRASER H: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart (2006) 92(Suppl. 4):IV6-IV14.
16. CHAITMAN BR: Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation (2006) 113(20):2462-2472.
17. ANTZELEVITCH C, BELARDINELLI L, ZYGMUNT AC et al.: Electrophysiological effects of ranolazine, a novel anti-anginal agent with antiarrhythmic properties. Circulation (2004) 110(8):904-910.
18. ROUSSEAU MF, POULEUR H, COCCO G, WOLFF AA: Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol. (2005) 95(3):311-316.
19. CHAITMAN BR, SKETTINO SL, PARKER JO et al.: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. (2004) 43(8): 1375-1382.
20. CHAITMAN BR, PEPINE CJ, PARKER JO et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA (2004) 291(3):309-316.
21. TIMMIS AD, CHAITMAN BR, CRAGER M: Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J. (2006) 27(1):42-48.
22. STONE PH, GRATSIANSKY NA, BLOKHIN A, HUANG IZ, MENG L: Anti-anginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol. (2006) 48(3):566-575.
23. MORROW DA, SCIRICA BM, KARWATOWSKA-PROKOPCZUK E et al.: Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am. Heart J. (2006) 51(6):1186.e1-e9.
24. MORROW DA, SCIRICA BM, KARWATOWSKA-PROKOPCZUK E et al.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA (2007) 297(16):1775-1783.
25. KOREN MJ, CRAGER MR, SWEENEY M: Long-term safety of a novel anti-anginal agent in patients with severe chronic stable angina: the ranolazine open label experience (ROLE). J. Am. College Cardiol. (2007) 49(10):1027-1034.